



**21** ST EDITION

---

# *Remington*

**The Science and Practice  
of Pharmacy**



**LIPPINCOTT WILLIAMS & WILKINS**

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

Editor: David B. Troy  
Managing Editor: Matthew J. Hauber  
Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street  
Baltimore, Maryland 21201-2436 USA

530 Walnut Street  
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved

Library of Congress Catalog Card Information is available  
ISBN 0-7817-4673-6

*The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.*

*The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.*

*Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.*

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.



# Contents

<b>Part 1 Orientation</b>		49	Biotechnology and Drugs . . . . .	976	
1	Scope of Pharmacy . . . . .	3	Aerosols . . . . .	1000	
2	Evolution of Pharmacy . . . . .	7	Quality Assurance and Control . . . . .	1018	
3	Ethics and Professionalism . . . . .	20	Stability of Pharmaceutical Products . . . . .	1025	
4	The Practice of Community Pharmacy . . . . .	30	Bioavailability and Bioequivalency Testing . . . . .	1037	
5	Pharmacists in Industry . . . . .	35	Plastic Packaging Materials . . . . .	1047	
6	Pharmacists in Government . . . . .	40	Pharmaceutical Necessities . . . . .	1058	
7	Pharmacists and Public Health . . . . .	51			
8	Information Resources in Pharmacy and the Pharmaceutical Sciences . . . . .	64	<b>Part 6 Pharmacokinetics and Pharmacodynamics</b>		
9	Clinical Drug Literature . . . . .	74	56	Diseases: Manifestations and Pathophysiology . . . . .	1095
10	Research . . . . .	87	57	Drug Absorption, Action, and Disposition . . . . .	1142
<b>Part 2 Pharmaceutics</b>			58	Basic Pharmacokinetics and Pharmacodynamics . . . . .	1171
11	Metrology and Pharmaceutical Calculations . . . . .	99	59	Clinical Pharmacokinetics and Pharmacodynamics . . . . .	1191
12	Statistics . . . . .	127	60	Principles of Immunology . . . . .	1206
13	Molecular Structure, Properties, and States of Matter . . . . .	162	61	Adverse Drug Reactions and Clinical Toxicology . . . . .	1221
14	Complex Formation . . . . .	186	62	Pharmacogenomics . . . . .	1230
15	Thermodynamics . . . . .	201	63	Pharmacokinetics/Pharmacodynamics in Drug Development . . . . .	1249
16	Solutions and Phase Equilibria . . . . .	211	<b>Part 7 Pharmaceutical and Medicinal Agents</b>		
17	Ionic Solutions and Electrolytic Equilibria . . . . .	231	64	Diagnostic Drugs and Reagents . . . . .	1261
18	Tonicity, Osmoticity, Osmolality, and Osmolarity . . . . .	250	65	Topical Drugs . . . . .	1277
19	Chemical Kinetics . . . . .	266	66	Gastrointestinal and Liver Drugs . . . . .	1294
20	Interfacial Phenomena . . . . .	280	67	Blood, Fluids, Electrolytes, and Hematological Drugs . . . . .	1318
21	Colloidal Dispersions . . . . .	293	68	Cardiovascular Drugs . . . . .	1350
22	Coarse Dispersions . . . . .	319	69	Respiratory Drugs . . . . .	1371
23	Rheology . . . . .	338	70	Sympathomimetic Drugs . . . . .	1379
<b>Part 3 Pharmaceutical Chemistry</b>			71	Cholinomimetic Drugs . . . . .	1389
24	Inorganic Pharmaceutical Chemistry . . . . .	361	72	Adrenergic Antagonists and Adrenergic Neuron Blocking Drugs . . . . .	1399
25	Organic Pharmaceutical Chemistry . . . . .	386	73	Antimuscarinic and Antispasmodic Drugs . . . . .	1405
26	Natural Products . . . . .	410	74	Skeletal Muscle Relaxants . . . . .	1411
27	Drug Nomenclature—United States Adopted Names . . . . .	443	75	Diuretic Drugs . . . . .	1422
28	Structure-Activity Relationship and Drug Design . . . . .	468	76	Uterine and Antimigraine Drugs . . . . .	1432
29	Fundamentals of Medical Radionuclides . . . . .	479	77	Hormones and Hormone Antagonists . . . . .	1437
<b>Part 4 Pharmaceutical Testing, Analysis, and Control</b>			78	General Anesthetics . . . . .	1474
30	Analysis of Medicinals . . . . .	495	79	Local Anesthetics . . . . .	1479
31	Biological Testing . . . . .	553	80	Antianxiety Agents and Hypnotic Drugs . . . . .	1486
32	Clinical Analysis . . . . .	565	81	Antiepileptic Drugs . . . . .	1501
33	Chromatography . . . . .	599	82	Psychopharmacologic Agents . . . . .	1509
34	Instrumental Methods of Analysis . . . . .	633	83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs . . . . .	1524
35	Dissolution . . . . .	672	84	Histamine and Antihistaminic Drugs . . . . .	1543
<b>Part 5 Pharmaceutical Manufacturing</b>			85	Central Nervous System Stimulants . . . . .	1551
36	Separation . . . . .	691	86	Antineoplastic Drugs . . . . .	1556
37	Powders . . . . .	702	87	Immunoactive Drugs . . . . .	1588
38	Property-Based Drug Design and Preformulation . . . . .	720	88	Parasiticides . . . . .	1595
39	Solutions, Emulsions, Suspensions, and Extracts . . . . .	745	89	Immunizing Agents and Allergenic Extracts . . . . .	1600
40	Sterilization . . . . .	776	90	Anti-Infectives . . . . .	1626
41	Parenteral Preparations . . . . .	802	91	Enzymes . . . . .	1685
42	Intravenous Admixtures . . . . .	837	92	Nutrients and Associated Substances . . . . .	1688
43	Ophthalmic Preparations . . . . .	850	93	Pesticides . . . . .	1719
44	Medicated Topicals . . . . .	871	<b>Part 8 Pharmacy Practice</b>		
45	Oral Solid Dosage Forms . . . . .	889	<b>A Fundamentals of Pharmacy Practice</b>		
46	Coating of Pharmaceutical Dosage Forms . . . . .	929	94	Application of Ethical Principles to Practice Dilemmas . . . . .	1745
47	Extended-Release and Targeted Drug Delivery Systems . . . . .	939	95	Technology and Automation . . . . .	1753
48	The New Drug Approval Process and Clinical Trial Design . . . . .	965	96	The Patient: Behavioral Determinants . . . . .	1762
			97	Patient Communication . . . . .	1770
			98	Patient Compliance . . . . .	1782
			99	Drug Education . . . . .	1796

100	Professional Communications . . . . .	1808	117	Documenting, Billing, and Reimbursement for Pharmaceutical Care Services . . . . .	2114
101	The Prescription . . . . .	1823	118	Pharmaceutical Risk Management . . . . .	2124
102	Providing a Framework for Ensuring Medication Use Safety . . . . .	1840	119	Integrated Health Care Delivery Systems . . . . .	2130
103	Poison Control . . . . .	1881	<b>C Patient Care</b>		
104	Drug Interactions . . . . .	1889	120	Specialization in Pharmacy Practice . . . . .	2155
105	Extemporaneous Prescription Compounding . . . . .	1903	121	Pharmacists and Disease State Management . . . . .	2163
106	Nuclear Pharmacy Practice . . . . .	1913	122	Development of a Pharmacy Care Plan and Patient Problem-Solving . . . . .	2170
107	Nutrition in Pharmacy Practice . . . . .	1925	123	Ambulatory Patient Care . . . . .	2179
108	Pharmacoepidemiology . . . . .	1958	124	Self-Care . . . . .	2197
109	Surgical Supplies . . . . .	1968	125	Diagnostic Self-Care . . . . .	2206
110	Health Accessories . . . . .	1979	126	Preventive Care . . . . .	2223
<b>B Social, Behavioral, Economic, and Administrative Sciences</b>			127	Hospital Pharmacy Practice . . . . .	2247
111	Laws Governing Pharmacy . . . . .	2015	128	Emergency Medicine Pharmacy Practice . . . . .	2265
112	Re-engineering Pharmacy Practice . . . . .	2055	129	Long-Term Care . . . . .	2272
113	Pharmacoeconomics . . . . .	2070	130	Aseptic Processing for Home Infusion Pharmaceuticals . . . . .	2290
114	Community Pharmacy Economics and Management . . . . .	2082	131	The Pharmacist's Role in Substance Use Disorders . . . . .	2303
115	Product Recalls and Withdrawals . . . . .	2098	132	Complementary and Alternative Medical Health Care . . . . .	2318
116	Marketing Pharmaceutical Care Services . . . . .	2107	133	Chronic Wound Care . . . . .	2342



# Parenteral Preparations

Michael J Akers, PhD

Parenteral (Gk, *para enteron*, beside the intestine) dosage forms differ from all other drug dosage forms because they are injected directly into body tissue through the primary protective system of the human body, the skin, and mucous membranes. They must be exceptionally pure and free from physical, chemical, and biological contaminants. These requirements place a heavy responsibility on the pharmaceutical industry to practice current good manufacturing practices (cGMPs) in the manufacture of parenteral dosage forms and upon pharmacists and other health care professionals to practice good aseptic practices (GAPs) in dispensing them for administration to patients.

Certain pharmaceutical agents, particularly peptides, proteins, and many chemotherapeutic agents, can only be given parenterally because they are inactivated in the gastrointestinal tract when given by mouth. Parenterally administered drugs are relatively unstable and generally high potent drugs that require strict control of their administration to the patient. Because of the advent of biotechnology, parenteral products have grown in number and usage around the world.

This chapter will focus on the unique characteristics of parenteral dosage forms and the basic principles for formulating, packaging, manufacturing, and controlling the quality of these unique products. The references and bibliography at the end of this chapter contain the most up-to-date texts, book chapters, and review papers on parenteral product formulation, manufacture, and quality control.

## OVERVIEW OF UNIQUE CHARACTERISTICS OF PARENTERAL DOSAGE FORMS

Parenteral products are unique from any other type of pharmaceutical dosage form for the following reasons:

- All products must be sterile.
- All products must be free from pyrogenic (endotoxin) contamination.
- Injectable solutions must be free from visible particulate matter. This includes reconstituted sterile powders.
- Products should be isotonic although strictness of isotonicity depends on the route of administration. Products to be administered into the cerebrospinal fluid must be isotonic. Ophthalmic products, while not parenteral, also must be isotonic. Products to be administered by bolus injection by routes other than intravenous (IV) essentially should be isotonic or at least very close to isotonicity. IV infusions must be isotonic.

*The author recognizes the long time contributions of Dr. Kenneth Avis. Dr. Avis died in January 1999. Dr. Avis authored this chapter in Remington since 1965. To honor his memory, the author has maintained most of his organization of this chapter with new material and revised information added where appropriate.*

802

- All products must be stable (not only chemically and physically like all other dosage forms, but also "stable" microbiologically, i.e., sterility, freedom from pyrogenic and visible particulate contamination) must be maintained throughout the shelflife of the product.
- Products must be compatible (if applicable) with IV diluents, delivery systems, and other drug products co-administered.

## FORMULATION PRINCIPLES

Parenteral drugs are formulated as solutions, suspensions, emulsions, liposomes, microspheres, nanosystems, and powders to be reconstituted as solutions. This section will describe the components that are commonly used in parenteral formulations focusing on solutions and freeze-dried products. General guidance also will be provided on appropriate selection of the finished sterile dosage form and initial approaches used to develop the optimal parenteral formulation.

## VEHICLES

**WATER**—Since most liquid injections are quite dilute, the component present in the highest proportion is the vehicle. The vehicle of greatest importance for parenteral products is water. Water of suitable quality for compounding and rinsing product contact surfaces may be prepared either by distillation or by reverse osmosis, to meet United States Pharmacopeia (USP) specifications for Water for Injection (WFI). Only by these two methods is it possible to separate adequately various liquid, gas, and solid contaminating substances from water. These two methods for preparation of WFI and specifications for WFI are discussed later in this chapter. With the possible exception of freeze-drying, there is no unit operation more important and none more costly to install and operate than the one for the preparation of WFI.

**WATER-MISCIBLE VEHICLES**—A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. These solvents are used primarily to solubilize certain drugs in an aqueous vehicle and to reduce hydrolysis. The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol, and propylene glycol. Ethyl alcohol is used particularly in the preparation of solutions of cardiac glycosides and the glycols in solutions of barbiturates, certain alkaloids, and certain antibiotics. Such preparations usually are given intramuscularly. There are limitations with the amount of these co-solvents that can be administered because of toxicity concerns, greater potential for hemolysis, and potential for drug precipitation at the site of injection.<sup>1</sup> Formulation scientists needing to use one or more of these solvents must consult the literature (eg, reference<sup>2</sup>) and toxicologists to ascertain the maximum amount of co-solvents

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.